Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune responses and local adverse reactions after the fifth acellular pertussis vaccination in Dutch 4-year-old children
NL-OMON35976Active, not recruiting
- Sponsor
- National Institutes of Health
- Start
- Jan 2012
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of tetanus toxoid + diphtheria toxoid + acellular pertussis + inactivated poliovirus vaccine in pertussis (2 arms), sponsored by National Institutes of Health. Primary endpoints: Pertussis-specific memory T-cell cytokine responses, Pertussis component-specific IgG subclass and IgE responses and 2 more. Started Jan 2012; status: active, not recruiting.
02
Drugs
tetanus toxoid + diphtheria toxoid + acellular pertussis + inactivated poliovirus vaccine
03
Conditions
pertussis
Beyond the preview
Go deeper on NL-OMON35976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35976.